



Neuland Laboratories Limited
11th Floor (5th Office Level),
Phoenix IVY Building,
Plot No.573A-III, Road No.82,
Jubilee Hills, Hyderabad - 500033,
Telangana, India.

Tel: 040 67611600 / 67611700
Email: neuland@neulandlabs.com
www.neulandlabs.com

May 4, 2023

To
BSE Limited
Phiroze Jeejeebhoy Towers, 25th Floor,
Dalal Street, Mumbai - 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Results Release and Earnings Call Notice

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith the schedule of Q4 and full year FY 2023 Earnings Call details.

This is for your information and records.

Thanking you,

Yours faithfully,
For Neuland Laboratories Limited

Sarada Bhamidipati
Company Secretary

Encl: As above



Neuland Laboratories Limited's Q4 and FY23 Results Conference Call

Neuland Laboratories Limited will announce its results for the fourth quarter and financial year ended March 31, 2023 on May 11, 2023. The results will also be made available on the website of the Company, www.neulandlabs.com

Following the announcement, the management of the Company will host an Earnings Call on May 11, 2023 at 17:30 hrs.

The details of the earnings call are:

Date:
May 11, 2023

Time:
17:30 Hrs (IST)

For Diamond Pass Registration Please Click Here:

[Diamond Pass](#)

About Neuland Laboratories Limited (BSE:524558, NSE: NEULANLAB)

For over 39 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 900 Regulatory filings in the US (62 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001.

For more information, visit www.NeulandLabs.com

For more queries please contact:

Neuland: ir@neulandlabs.com

Ravi Udeshi: ravi.udeshi@in.ey.com